Locus Biosciences will conduct a clinical trial for its Ai-designed bacteriophage therapeutic for HAP/VAP caused by antibiotic-resistant P. aeruginosa.
RT’s Three Key Takeaways:
- Federal support for phage therapy –…
$3.3M Trial of Ai-Designed Bacteriophage Therapy for HAP/VAP
